“Non-criteria” antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort

• Published in: Arthritis research & therapy Vol. 22; no. 1; pp. 33 - 11
• Main Authors: Liu, Tingting, Gu, Jieyu, Wan, Liyan, Hu, Qiongyi, Teng, Jialin, Liu, Honglei, Cheng, Xiaobing, Ye, Junna, Su, Yutong, Sun, Yue, Zhou, Jinfeng, Norman, Gary L., Wang, Xuefeng, Yang, Chengde, Shi, Hui
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21.02.2020; BioMed Central; BMC
• Subjects: Anti-phosphatidylserine/prothrombin antibodies; Anti-β2-glycoprotein I Domain 1; Antibodies; Anticoagulants; Antiphospholipid antibodies; Antiphospholipid syndrome; Arthritis; Autoimmune diseases; Biological markers; Biomarkers; Cardiolipin; Classification; Diagnosis; Diseases; Glycoproteins; Health aspects; IgA isotype; Immunoglobulin A; Immunoglobulin G; Immunoglobulins; Laboratories; Lupus; Medical diagnosis; Medical schools; Membrane lipids; Migraine; Morbidity; Non-criteria antiphospholipid antibodies; Obstetrics; Patients; Physiological aspects; Pregnancy; Proteins; Rheumatoid arthritis; Rheumatology; Statistical analysis; Thrombosis; China; United States > US; IgA isotype; Non-criteria antiphospholipid antibodies; Anti-β2-glycoprotein I Domain 1; Anti-phosphatidylserine/prothrombin antibodies; Antiphospholipid syndrome

Despite expansion in the 2006 Sydney antiphospholipid syndrome (APS) classification criteria to include IgG/IgM anti-β2-glycoprotein (aβ2GPI) antibodies in addition to IgG/IgM anti-cardiolipin antibodies (aCL) and lupus anticoagulant (LAC), some individuals with clinical features of APS remain seron...